You are here

setmelanotide

Looking to win over some skeptical analysts, Rhythm beats the drum on interim data in PhII basket study for additional indications

Endpoints

Tue, 01/26/21 - 11:19 am

Rhythm Pharmaceuticals

clinical trials

Rhythm Pharma knocked off stride as mixed PhIII obesity data for its sole big drug look ‘meh’ to many

Endpoints

Tue, 12/22/20 - 10:54 am

Rhythm Pharmaceuticals

clinical trials

FDA gives Rhythm the green light for setmelanotide, a drug aimed at reducing obesity in certain genetic disorders

Endpoints

Mon, 11/30/20 - 10:38 am

Rhythm Pharmaceuticals

Rhythm Pharma Files Drug Application, Names Hunter Smith Interim CEO

Xconomy

Tue, 03/31/20 - 10:07 pm

Rhythm Pharmaceuticals

Rhythm’s genetic obesity drug hits primary endpoint in phase 3

Fierce Biotech

Wed, 08/7/19 - 10:43 am

Rhythm Pharmaceuticals

genetic obesity

clinical trials